Loading…

Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as pr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 2019-10, Vol.36 (5), p.433-439
Main Authors: Gómez-Ruiz, Álvaro Jesús, González-Gil, Alida, Gil, José, Navarro-Barrios, Álvaro, Alconchel, Felipe, Gil, Elena, Martínez, Jerónimo, Nieto, Aníbal, Barceló, Francisco, Cascales-Campos, Pedro Antonio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213
cites cdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213
container_end_page 439
container_issue 5
container_start_page 433
container_title Clinical & experimental metastasis
container_volume 36
creator Gómez-Ruiz, Álvaro Jesús
González-Gil, Alida
Gil, José
Navarro-Barrios, Álvaro
Alconchel, Felipe
Gil, Elena
Martínez, Jerónimo
Nieto, Aníbal
Barceló, Francisco
Cascales-Campos, Pedro Antonio
description In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.
doi_str_mv 10.1007/s10585-019-09982-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2252269981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2251464952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0EokvhBTggS1yKhMF_kjg5rralXamiK6WcI8eegKvEWex4Ud6LB8TZLSBx4GTZ88031vwQes3oB0ap_BgYzcucUFYRWlUlJ-wJWrFcCiK5LJ6iFeUFJ7SsyjP0IoQHSmkmZfkcnQnGJZWCrdDPHXg7jQ5Uj-voO6UBX9oAKgCu4bAUZ1zr0QO-2NWXdf3uPV5f35FwfFLO4Pvt-jMeRgM9tg7v1WTBTQH_sNM3vO_T1cWBBHDBTvYA2IOO3icEjwflrXJYK6fB48mDmsDgdsZ6npLdRH3sCNF_BT8nWQz4Zru72rxEzzrVB3j1eJ6jL5-u7jc35PbuertZ3xItZD4RWaiy1ErSLG-F4sqYruWcFarLqqxVLKfATKm4BKAiK1qWt5ILQ4WuDGWciXN0cfLu_fg9QpiawQYNfa8cjDE0nOecF2n1C_r2H_RhjN6l3y0Uy4qsynmi-InSfgzBQ9fsvR2UnxtGmyXT5pRpkzJtjpk2i_rNozq2A5g_Lb9DTIA4ASGVXNrV39n_0f4CcdiuCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2251464952</pqid></control><display><type>article</type><title>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</title><source>Springer Link</source><creator>Gómez-Ruiz, Álvaro Jesús ; González-Gil, Alida ; Gil, José ; Navarro-Barrios, Álvaro ; Alconchel, Felipe ; Gil, Elena ; Martínez, Jerónimo ; Nieto, Aníbal ; Barceló, Francisco ; Cascales-Campos, Pedro Antonio</creator><creatorcontrib>Gómez-Ruiz, Álvaro Jesús ; González-Gil, Alida ; Gil, José ; Navarro-Barrios, Álvaro ; Alconchel, Felipe ; Gil, Elena ; Martínez, Jerónimo ; Nieto, Aníbal ; Barceló, Francisco ; Cascales-Campos, Pedro Antonio</creatorcontrib><description>In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.</description><identifier>ISSN: 0262-0898</identifier><identifier>EISSN: 1573-7276</identifier><identifier>DOI: 10.1007/s10585-019-09982-1</identifier><identifier>PMID: 31270731</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Chemotherapy ; Combined Modality Therapy ; Cytoreduction Surgical Procedures - methods ; Decision making ; Female ; Follow-Up Studies ; Gastric cancer ; Hematology ; Humans ; Hyperthermia, Induced - methods ; Middle Aged ; Models, Statistical ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Nomograms ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Peritoneal Neoplasms - pathology ; Peritoneal Neoplasms - therapy ; Peritoneum ; Platinum ; Platinum - administration &amp; dosage ; Prognosis ; Prospective Studies ; Research Paper ; Severity of Illness Index ; Surgery ; Surgical Oncology ; Survival Rate ; Taxoids - administration &amp; dosage</subject><ispartof>Clinical &amp; experimental metastasis, 2019-10, Vol.36 (5), p.433-439</ispartof><rights>Springer Nature B.V. 2019</rights><rights>Clinical &amp; Experimental Metastasis is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</citedby><cites>FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</cites><orcidid>0000-0002-4056-0251</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31270731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Ruiz, Álvaro Jesús</creatorcontrib><creatorcontrib>González-Gil, Alida</creatorcontrib><creatorcontrib>Gil, José</creatorcontrib><creatorcontrib>Navarro-Barrios, Álvaro</creatorcontrib><creatorcontrib>Alconchel, Felipe</creatorcontrib><creatorcontrib>Gil, Elena</creatorcontrib><creatorcontrib>Martínez, Jerónimo</creatorcontrib><creatorcontrib>Nieto, Aníbal</creatorcontrib><creatorcontrib>Barceló, Francisco</creatorcontrib><creatorcontrib>Cascales-Campos, Pedro Antonio</creatorcontrib><title>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</title><title>Clinical &amp; experimental metastasis</title><addtitle>Clin Exp Metastasis</addtitle><addtitle>Clin Exp Metastasis</addtitle><description>In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures - methods</subject><subject>Decision making</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hyperthermia, Induced - methods</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Nomograms</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Peritoneum</subject><subject>Platinum</subject><subject>Platinum - administration &amp; dosage</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Research Paper</subject><subject>Severity of Illness Index</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Taxoids - administration &amp; dosage</subject><issn>0262-0898</issn><issn>1573-7276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQhy0EokvhBTggS1yKhMF_kjg5rralXamiK6WcI8eegKvEWex4Ud6LB8TZLSBx4GTZ88031vwQes3oB0ap_BgYzcucUFYRWlUlJ-wJWrFcCiK5LJ6iFeUFJ7SsyjP0IoQHSmkmZfkcnQnGJZWCrdDPHXg7jQ5Uj-voO6UBX9oAKgCu4bAUZ1zr0QO-2NWXdf3uPV5f35FwfFLO4Pvt-jMeRgM9tg7v1WTBTQH_sNM3vO_T1cWBBHDBTvYA2IOO3icEjwflrXJYK6fB48mDmsDgdsZ6npLdRH3sCNF_BT8nWQz4Zru72rxEzzrVB3j1eJ6jL5-u7jc35PbuertZ3xItZD4RWaiy1ErSLG-F4sqYruWcFarLqqxVLKfATKm4BKAiK1qWt5ILQ4WuDGWciXN0cfLu_fg9QpiawQYNfa8cjDE0nOecF2n1C_r2H_RhjN6l3y0Uy4qsynmi-InSfgzBQ9fsvR2UnxtGmyXT5pRpkzJtjpk2i_rNozq2A5g_Lb9DTIA4ASGVXNrV39n_0f4CcdiuCw</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Gómez-Ruiz, Álvaro Jesús</creator><creator>González-Gil, Alida</creator><creator>Gil, José</creator><creator>Navarro-Barrios, Álvaro</creator><creator>Alconchel, Felipe</creator><creator>Gil, Elena</creator><creator>Martínez, Jerónimo</creator><creator>Nieto, Aníbal</creator><creator>Barceló, Francisco</creator><creator>Cascales-Campos, Pedro Antonio</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4056-0251</orcidid></search><sort><creationdate>20191001</creationdate><title>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</title><author>Gómez-Ruiz, Álvaro Jesús ; González-Gil, Alida ; Gil, José ; Navarro-Barrios, Álvaro ; Alconchel, Felipe ; Gil, Elena ; Martínez, Jerónimo ; Nieto, Aníbal ; Barceló, Francisco ; Cascales-Campos, Pedro Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures - methods</topic><topic>Decision making</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hyperthermia, Induced - methods</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Nomograms</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Peritoneum</topic><topic>Platinum</topic><topic>Platinum - administration &amp; dosage</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Research Paper</topic><topic>Severity of Illness Index</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Taxoids - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Ruiz, Álvaro Jesús</creatorcontrib><creatorcontrib>González-Gil, Alida</creatorcontrib><creatorcontrib>Gil, José</creatorcontrib><creatorcontrib>Navarro-Barrios, Álvaro</creatorcontrib><creatorcontrib>Alconchel, Felipe</creatorcontrib><creatorcontrib>Gil, Elena</creatorcontrib><creatorcontrib>Martínez, Jerónimo</creatorcontrib><creatorcontrib>Nieto, Aníbal</creatorcontrib><creatorcontrib>Barceló, Francisco</creatorcontrib><creatorcontrib>Cascales-Campos, Pedro Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical &amp; experimental metastasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Ruiz, Álvaro Jesús</au><au>González-Gil, Alida</au><au>Gil, José</au><au>Navarro-Barrios, Álvaro</au><au>Alconchel, Felipe</au><au>Gil, Elena</au><au>Martínez, Jerónimo</au><au>Nieto, Aníbal</au><au>Barceló, Francisco</au><au>Cascales-Campos, Pedro Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</atitle><jtitle>Clinical &amp; experimental metastasis</jtitle><stitle>Clin Exp Metastasis</stitle><addtitle>Clin Exp Metastasis</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>36</volume><issue>5</issue><spage>433</spage><epage>439</epage><pages>433-439</pages><issn>0262-0898</issn><eissn>1573-7276</eissn><abstract>In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>31270731</pmid><doi>10.1007/s10585-019-09982-1</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4056-0251</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0262-0898
ispartof Clinical & experimental metastasis, 2019-10, Vol.36 (5), p.433-439
issn 0262-0898
1573-7276
language eng
recordid cdi_proquest_miscellaneous_2252269981
source Springer Link
subjects Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Chemotherapy
Combined Modality Therapy
Cytoreduction Surgical Procedures - methods
Decision making
Female
Follow-Up Studies
Gastric cancer
Hematology
Humans
Hyperthermia, Induced - methods
Middle Aged
Models, Statistical
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Nomograms
Oncology
Ovarian cancer
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Peritoneal Neoplasms - pathology
Peritoneal Neoplasms - therapy
Peritoneum
Platinum
Platinum - administration & dosage
Prognosis
Prospective Studies
Research Paper
Severity of Illness Index
Surgery
Surgical Oncology
Survival Rate
Taxoids - administration & dosage
title Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A25%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peritoneal%20Surface%20Disease%20Severity%20Score%20(PSDSS),%20AGO-score%20and%20TIAN%20model%20in%20patients%20with%20platinum-sensitive%20recurrent%20ovarian%20cancer%20treated%20by%20cytoreductive%20surgery%20plus%20HIPEC&rft.jtitle=Clinical%20&%20experimental%20metastasis&rft.au=G%C3%B3mez-Ruiz,%20%C3%81lvaro%20Jes%C3%BAs&rft.date=2019-10-01&rft.volume=36&rft.issue=5&rft.spage=433&rft.epage=439&rft.pages=433-439&rft.issn=0262-0898&rft.eissn=1573-7276&rft_id=info:doi/10.1007/s10585-019-09982-1&rft_dat=%3Cproquest_cross%3E2251464952%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2251464952&rft_id=info:pmid/31270731&rfr_iscdi=true